Tamano Ryuta, Ishida Mitsuhiro, Asaki Toshiyuki, Hasegawa Minoru, Shinohara Shunji
Department of Pain and Neuroscience, Discovery Research Laboratory for Core Therapeutic Areas, Shionogi & Co., Ltd., 1-1 3chome, Futaba-cho, Toyonaka, Osaka 561-0825, Japan.
Department of Clinical Development, Shionogi & Co., Ltd., 12F Hankyu Terminal Building, 1-4 Shibata 1-chome, Kita-ku, Osaka 530-0012, Japan.
Neurosci Lett. 2016 Feb 26;615:78-82. doi: 10.1016/j.neulet.2016.01.025. Epub 2016 Jan 19.
Dysfunction in the central serotonin (5-HT) and norepinephrine (NE) systems cause depression and pain. Descending spinal pain modulatory pathways are important in the analgesic mechanisms of antidepressants, particularly serotonin and norepinephrine reuptake inhibitors (SNRIs). While many non-clinical studies have demonstrated the roles of central monoaminergic systems in pain, there is little evidence to illuminate the direct contribution of spinal descending pain modulatory systems independently of depressive-like behavior. To examine the effects of dysfunction of spinal monoaminergic systems on pain sensitivity, we established a rat chronic pain model by administering lumbar-intrathecal reserpine to minimize its influence on brain. Lumbar-intrathecal reserpine evoked persistent mechanical hypersensitivity and corresponding reductions in spinal 5-HT and NE concentrations (from 767.2 to 241.6ng/g and from 455.9 to 41.7ng/g, respectively after reserpine 30nmol). Lumbar-intrathecal reserpine did not deplete brain monoamines or bring about depressive-like behavior in the forced swim test. Spinal monoamines depletion-induced pain sensitivity was ameliorated by lumbar-intrathecal administration of the SNRIs (duloxetine and milnacipran) in dose-dependent manners. These suggest that increased pain sensitivity could be induced by dysfunction solely of the descending pain modulatory system, regardless of depressive-like behavior, and lumbar-intrathecal administration of SNRIs could ameliorate the pain sensitivity which might be mediated by affecting the descending pain modulatory system in the spinal cord, not via their antidepressant effects.
中枢5-羟色胺(5-HT)和去甲肾上腺素(NE)系统功能障碍会导致抑郁和疼痛。脊髓下行性疼痛调制通路在抗抑郁药的镇痛机制中起重要作用,尤其是5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRIs)。虽然许多非临床研究已经证明中枢单胺能系统在疼痛中的作用,但几乎没有证据表明脊髓下行性疼痛调制系统在不依赖抑郁样行为的情况下的直接作用。为了研究脊髓单胺能系统功能障碍对疼痛敏感性的影响,我们通过腰椎鞘内注射利血平建立了大鼠慢性疼痛模型,以尽量减少其对大脑的影响。腰椎鞘内注射利血平可诱发持续的机械性超敏反应,并相应降低脊髓5-HT和NE浓度(利血平30nmol注射后,分别从767.2ng/g降至241.6ng/g和从455.9ng/g降至41.7ng/g)。腰椎鞘内注射利血平不会消耗脑内单胺,也不会在强迫游泳试验中引起抑郁样行为。腰椎鞘内给予SNRIs(度洛西汀和米那普明)以剂量依赖的方式改善了脊髓单胺耗竭诱导的疼痛敏感性。这些结果表明,仅下行性疼痛调制系统功能障碍就可诱发疼痛敏感性增加,而与抑郁样行为无关,腰椎鞘内给予SNRIs可改善疼痛敏感性,这可能是通过影响脊髓中的下行性疼痛调制系统介导的,而非通过其抗抑郁作用。